May 2025 – Zug, Switzerland: RGCC International is proud to announce the signing of a Letter of Intent (LoI) with Universitas Hasanuddin in Indonesia and PT Wapindo Jasaartha (Klinik Simas Sehat), marking the beginning of a collaborative academic partnership.
This partnership reflects a shared commitment to fostering international academic collaboration and enabling knowledge exchange across institutions in regards to advanced cancer diagnostic technologies.
The partnership focuses on establishing and strengthening institutional collaboration, promoting mutual understanding through research collaboration, cultural exchange, and academic mobility.
“At RGCC, we believe that meaningful scientific progress is built on collaboration, education, and the open exchange of ideas,” said Dr. Ioannis Papasotiriou, Director of RGCC International. “This agreement represents an important step toward uniting global expertise to advance personalized cancer diagnostics and improve patient outcomes worldwide.”
All parties have affirmed their intent to work together to explore joint initiatives, with a focus on enhancing understanding and application of advanced cancer diagnostic technologies.
About RGCC International:
RGCC was launched in 2004 by genetics pioneer Dr. Ioannis Papasotiriou who believes that the key to effectively treating cancer lies in personalized medicine. Today, RGCC is a leading innovator in the field of oncology diagnostics. Using world-leading technology, equipment, and innovative techniques, our team of scientists has developed a range of liquid biopsies that help physicians track cancer progression and tailor treatment plans based on individual patient profiles.
For general inquiries, please contact: [email protected]